Nektar Therapeutics (NKTR) Director Jeffrey Ajer Receives RSU Award

What Happened
Jeffrey Ajer, a director of Nektar Therapeutics (NKTR), received equity awards on 2026-09-23 totaling 6,000 adjusted units: 2,000 restricted stock units (RSUs) and a 4,000-unit derivative award. Both awards were granted at $0.00 (no purchase price), so the reported cash outlay at grant was $0. The filing lists the 2,000 as common stock acquired via RSUs and the 4,000 as a derivative award (stock option/derivative).

Key Details

• Transaction date: 2026-09-23; Form 4 filed: 2026-09-25 (timely, no late filing flag).
• Reported amounts: 2,000 shares (RSU) + 4,000 derivative units = 6,000 adjusted units; grant price $0.00.
• Vesting: the 2,000 RSU award vests in full one year after Sept 23, 2026; the 4,000 derivative award vests in substantially equal monthly installments over the one-year period beginning Sept 23, 2026 (per filing footnotes).
• Reverse split: all amounts were adjusted for a 1-for-15 reverse stock split effective June 8, 2025.
• Shares owned after the transaction: not specified in the provided filing details.

Context
These awards are compensation grants, not open-market purchases or sales. RSUs are rights to receive shares upon vesting; the derivative award appears to be an equity instrument that vests monthly over a year. Awards at grant are routine for directors and do not, by themselves, indicate whether the insider will buy or sell stock in the future.